1.84
+0.06(+3.37%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.76 |
| Day High | 1.84 |
| Day Low | 1.76 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 147,912 |
| Average Volume | 3.15M |
| Market Cap | 8.79M |
| PE | -0.2 |
| EPS | -9.08 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 2.39 |
| Change | 0.06 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of May 18, 2025 at a share price of $1.84. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $7.44 as of May 18, 2025 at a share price of $1.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Newsfile
May 15, 2025 8:15 PM GMT
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Newsfile
May 07, 2025 11:45 AM GMT
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatol
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Newsfile
Apr 09, 2025 11:45 AM GMT
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHI